Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget: Volume 12, Issue 25.
Oncotarget’s Volume 12, Issue 25
Cover (Research Paper): Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas
Origin: California, Pennsylvania, Washington, D.C., Rhode Island, Michigan, United States; Kanagawa, Japan
Institutions: University of Southern California, Caris Life Sciences, Fox Chase Center, Georgetown Lombardi Comprehensive Cancer Center, The Warren Alpert Medical School of Brown University, Wayne State University School of Medicine and The Barbara Karmanos Cancer Institute, St. Marianna University, University of Utah
Quote: “Cancer/testis antigens (CTAs) are strongly expressed in some solid tumors but minimally expressed in normal tissue, making them appealing therapeutic targets. KK-LC-1 (CXorf61) has cytoplasmic expression in gastric, breast, and lung cancer.”
Research Paper: Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound
Origin: Toronto, Canada
Institutions: Sunnybrook Health Sciences Centre, University of Toronto, York University, Ryerson University
Quote: “The purpose of the study was to investigate the role of pre-treatment quantitative ultrasound (QUS)-radiomics in predicting recurrence for patients with locally advanced breast cancer (LABC).”
Research Paper: Beneficial effect of KYP-2047, a propyl-oligopeptidase inhibitor, on oral squamous cell carcinoma
Origin: Messina, Viagrande, Italy
Institutions: University of Messina, IOM Ricerca Srl, Istituto Oncologico del Mediterraneo
Quote: “Oral carcinogenesis has been linked to genetic mutations, chromosomal aberrations and viral factors. Apoptosis and angiogenesis play a key role in the development of oral cancer. Therefore, it is very important discover new therapeutic strategies to counteract oral cancer progression. This study aimed to investigate the effect of KYP-2047 in an in vitro model of TSCC and in vivo CAL27-xenograft model.”
Origin: Chicago, United States
Institution: Northwestern University
Quote: “In Zhang et al. we report a novel means of delivering paclitaxel across the blood-brain barrier (BBB) using lowintensity pulsed ultrasound (LIPU) and microbubbles. This study is the basis for repurposing albumin-bound paclitaxel (PTX) for the treatment of glioblastoma (GBM), an established chemotherapy agent that has demonstrated remarkable antitumor activity in preclinical GBM models.”
Research Perspective: Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects
Origin: Connecticut, United States
Institution: Lerna Consulting
Quote: “A distinctive feature of the SARS-CoV-2 spike protein is its ability to efficiently fuse cells, thus producing syncytia found in COVID-19 patients. This commentary proposes how this ability enables spike to cause COVID-19 complications as well as side effects of COVID-19 vaccines, and suggests how these effects can be prevented.”
Click here to read Oncotarget’s Volume 12, Issue 25.
YOU MAY ALSO LIKE: More Oncotarget Videos on LabTube
Oncotarget is a unique platform designed to house scientific studies in a journal format that is available for anyone to read without a paywall making access more difficult. This means information that has the potential to benefit our societies from the inside out can be shared with friends, neighbors, colleagues, and other researchers, far and wide.
For media inquiries, please contact email@example.com.